Details

Autor(en) / Beteiligte

• Tchétché, Didier
• Chevalier, Bernard
• Holzhey, David
• Harnath, Axel
• Schäfer, Ulrich
• Teiger, Emmanuel
• Manigold, Thibaut
• Modine, Thomas
• Souteyrand, Geraud
• Champagnac, Didier
• Oh, Jae K.
• Li, Shuzhen
• Verhoye, Jean-Philippe
• Kornowski, Ran
• Gilard, Martine
• Verhoye, Jean Philippe
• Leroux, Lionel
• Casassus, Frédéric
• Grisoli, Dominique
• Dambrin, Gregoire
• Marcheix, Bertrand
• Scholtz, Werner
• Kim, Won-Keun
• Guetta, Victor
• Ettori, Federica
• Petronio, Anna Sonia
• Bedogni, Francesco

Titel

TAVR for Failed Surgical Aortic Bioprostheses Using a Self-Expanding Device

Ist Teil von

• JACC. Cardiovascular interventions, 2019-05, Vol.12 (10), p.923-932

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2019

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The VIVA (Valve in Valve) trial was designed to systematically and prospectively collect data regarding the use of transcatheter aortic valve replacement in patients with failing surgical aortic bioprostheses at high-risk for reoperation. Surgical aortic valve replacement has been the standard of care in symptomatic patients with aortic valve disease. However, bioprosthetic valves degenerate over time, requiring redo surgery. VIVA is an international, observational, single-arm, postmarket study conducted at 23 sites that enrolled 202 patients with symptomatic degeneration of an aortic bioprosthesis eligible for elective treatment with a CoreValve or Evolut R self-expanding transcatheter aortic valve. Patients were elderly (mean age 79.9 years), 47.5% were men, and they had a mean Society of Thoracic Surgeons score of 6.6%. Although 41.8% of patients had surgical bioprostheses with labeled size ≤21 mm, valve hemodynamic parameters were markedly improved from baseline (mean aortic valve gradient 35.0 ± 16.3 mm Hg) to discharge (17.5 ± 8.6 mm Hg) and were sustained at 1 year (15.5 ± 7.5 mm Hg). At 1 year, total aortic regurgitation greater than mild was measured in 1.1% of patients. Clinical outcomes at 30 days demonstrated low mortality (2.5%), no disabling strokes, a 0.5% rate of acute kidney injury, and an 8.0% rate of new pacemaker implantation. At 1 year, the mortality rate remained low (8.8%), with 1 disabling stroke (0.6%). Five patients (2.5%) experienced coronary artery obstructions, 3 during and 1 immediately after the procedure and 1 several months later. Degenerated surgical bioprostheses can be safely treated with the CoreValve or Evolut R platform using the catheter-based valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in this real-world patient population. (CoreValve VIVA Study Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis; NCT02209298) [Display omitted]